Clinical trial
A Randomized, Double--blind, Placebo-controlled Phase III Study to Evaluate Active Immunization in Adjuvant Therapy of Patients with Stage IIIB and IIIC Melanoma with Natural Dendritic Cells Pulsed with Synthetic Peptides.
NCT02993315 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double--blind, Placebo-controlled Phase III Study to Evaluate Active Immunization in Adjuvant Therapy of Patients with Stage IIIB and IIIC Melanoma with Natural Dendritic Cells Pulsed with Synthetic Peptides.
- Lead sponsor
- Radboud University Medical Center
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- May 31, 2024
- Enrollment
- 148 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
melanoma (skin)